<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327223</url>
  </required_header>
  <id_info>
    <org_study_id>AMP-011</org_study_id>
    <nct_id>NCT00327223</nct_id>
  </id_info>
  <brief_title>Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy</brief_title>
  <official_title>A Phase 1 Trial of AmplimexonÂ® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AmpliMed Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AmpliMed Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and
      pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three
      weeks. The objective of the study is to determine the maximally tolerated dose, the
      pharmacokinetics, and the toxicity of the drug on the designated schedule.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximally tolerated dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>determine the pharmacokinetics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>determine the toxicity of the drug on the designated schedule</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>imexon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of imexon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imexon</intervention_name>
    <arm_group_label>imexon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously treated malignant disease of any type.

          -  Prior treatment; at least one prior regimen required.

          -  Able to perform the activities of daily living.

          -  Off prior cancer therapy for at least 4 weeks.

          -  If female, neither pregnant nor nursing.

          -  Willing to use contraceptives to prevent pregnancy.

          -  No other serious illnesses.

          -  No other active malignancy.

          -  No serious infections.

          -  No other current drug therapy for the cancer.

          -  Blood counts and blood chemistries in or near normal range.

          -  Prior radiation is permitted.

        Exclusion Criteria:

          -  No active brain metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Hersh, MD</last_name>
    <role>Study Director</role>
    <affiliation>AmpliMed Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Oncology Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Albany, New York Oncology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 014</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology, Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>March 12, 2008</last_update_submitted>
  <last_update_submitted_qc>March 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Evan Hersh, VP Medical Affairs</name_title>
    <organization>AmpliMed Corporation</organization>
  </responsible_party>
  <keyword>Metastatic cancer</keyword>
  <keyword>Disseminated malignant disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

